Additionally, MMR deficiency in these tumors leads to the loss of MMR proteins (dMMR), accumulation of somatic mutations, especially high instability in microsatellite sites, and activating the tumor immune microenvironment [3], which renders these tumors sensitive to immunotherapy [4]. This evidence concerns the gene MRC1 and neoplasm.